An analysis of a previously published phase III study prospectively validated five prognostic factors, referred to as the Moore criteria, used to identify a subset of patients with advanced cervical cancer that may not benefit from bevacizumab treatment.
For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
